Copyright
©The Author(s) 2024.
World J Hepatol. Oct 27, 2024; 16(10): 1158-1168
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1158
Published online Oct 27, 2024. doi: 10.4254/wjh.v16.i10.1158
Figure 2 Mechanisms of programmed cell death 1/programmed cell death ligand 1 axis in hepatocellular carcinoma.
HCC: Hepatocellular carcinoma; TCR: T cell receptor; PD-1: Programmed cell death 1; PD-L1: Programmed cell death ligand 1; MDSC: Myeloid derived suppressive cell.
Figure 3 Immunotherapy-based combination therapy for liver cancer.
TACE: Transartical chemoembolization.
- Citation: Cao WH, Zhang YQ, Li XX, Zhang ZY, Li MH. Advances in immunotherapy for hepatitis B virus associated hepatocellular carcinoma patients. World J Hepatol 2024; 16(10): 1158-1168
- URL: https://www.wjgnet.com/1948-5182/full/v16/i10/1158.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i10.1158